Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ataluren phase 2 dystrophin study in ambulatory nonsense mutation Duchenne muscular dystrophy
2019-001767-67Phase 2
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ataluren in Duchenne muscular dystrophy (DMD), sponsored by PTC Therapeutics, Inc. Primary endpoint: Percent Change From Baseline in Dystrophin Levels at Week 40, as Measured by ECL.
02
Drugs
ataluren
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on 2019-001767-67.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001767-67.